Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (611-620 of 934) with videos related to

Pageof 94
Sort By:
American Heart Journal|November 15, 2019
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United StatesChristopher P Cannon, James A de Lemos, Robert S Rosenson, et al.
Circulation|March 2, 2017
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)Matthew A Cavender, William B White, Petr Jarolim, et al.
JAMA Cardiology|August 25, 2021
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary SyndromeGorav Batra, Tatevik Ghukasyan Lakic, Johan Lindbäck, et al.
Journal of the American College of Cardiology|July 18, 2006
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgeryRajendra H Mehta, Matthew T Roe, Jyotsna Mulgund, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Journal of Thrombosis and Thrombolysis|January 24, 2004
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque ruptureC Michael Gibson, Ajay J Kirtane, Sabina A Murphy, et al.
BMC Genetics|December 3, 2008
Genomic complexity of the variable region-containing chitin-binding proteins in amphioxusLarry J Dishaw, M Gail Mueller, Natasha Gwatney, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
American Heart Journal|October 12, 2010
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart diseaseHarvey White, Claes Held, Ralph Stewart, et al.
Pageof 94

Showing results (611-620 of 934) with videos related to

Sort By:
Pageof 94
American Heart Journal|November 15, 2019
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United StatesChristopher P Cannon, James A de Lemos, Robert S Rosenson, et al.
Circulation|March 2, 2017
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)Matthew A Cavender, William B White, Petr Jarolim, et al.
JAMA Cardiology|August 25, 2021
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary SyndromeGorav Batra, Tatevik Ghukasyan Lakic, Johan Lindbäck, et al.
Journal of the American College of Cardiology|July 18, 2006
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgeryRajendra H Mehta, Matthew T Roe, Jyotsna Mulgund, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Journal of Thrombosis and Thrombolysis|January 24, 2004
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque ruptureC Michael Gibson, Ajay J Kirtane, Sabina A Murphy, et al.
BMC Genetics|December 3, 2008
Genomic complexity of the variable region-containing chitin-binding proteins in amphioxusLarry J Dishaw, M Gail Mueller, Natasha Gwatney, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
American Heart Journal|October 12, 2010
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart diseaseHarvey White, Claes Held, Ralph Stewart, et al.
Pageof 94